abcam

Product datasheet

Recombinant Human ProSAAS protein (denatured) ab174456

1 Image

Description

Product name	Recombinant Human ProSAAS protein (denatured)
Purity	> 85 % SDS-PAGE.
Expression system	Escherichia coli
Accession	Q9UHG2
Protein length	Full length protein
Animal free	No
Nature	Recombinant
Species	Human
Sequence	MGSSHHHHHHSSGLVPRGSHMGSMARPVKEPRGLSAAS PPLAETGAPRRF RRSVPRGEAAGAVQELARALAHLLEAERQERARAEAQE AEDQQARVLAQL LRVWGAPRNSDPALGLDDDPDAPAAQLARALLRARLDP AALAAQLVPAPV PAAALRPRPPVYDDGPAGPDAEEAGDETPDVDPELLRYL LGRILAGSADS EGVAAPRRLRRAADHDVGSELPPEGVLGALLRVKRLETP APQVPARRLLP P
Predicted molecular weight	27 kDa including tags
Amino acids	34 to 260
Tags	His tag N-Terminus
Additional sequence information	NCBI Accession No.: NP_037403
Description	Recombinant Human ProSAAS protein

Specifications

Our **Abpromise guarantee** covers the use of **ab174456** in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Applications	SDS-PAGE

Form	Liquid

Preparation and Storage

Stability and Storage	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. pH: 8.00 Constituents: 2.4% Urea, 10% Glycerol (glycerin, glycerine), 0.32% Tris HCl

General Info

Function	May function in the control of the neuroendocrine secretory pathway. Proposed be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the further processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 84 kDa form but not the autocatalytically derived 66 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. May control the intracellular timing of PCSK1 rather than its total level of activity. The function of the processed secreted peptides is not known.
Tissue specificity	Expressed in brain and pancreas.
Domain	ProSAAS(1-180) increases secretion of enzymatically inactive PCSK1. The C-terminal inhibitory domain is involved in inhibtion of PCSK1. It corresponds to the probable processing intermediate Big PEN-LEN, binds to PCSK1 in vitro and contains the hexapeptide L-L-R-V-K-R, which, as a synthetic peptide, is sufficient for PCSK1 inhibition.
Post-translational modifications	Proteolytically cleaved in the Golgi. O-glycosylated with a core 1 or possibly core 8 glycan.
Cellular localization	Secreted. Golgi apparatus > trans-Golgi network. A N-terminal processed peptide, probably Big SAAS or Little SAAS, is accumulated in cytoplasmic protein tau deposits in frontotemporal dementia and parkinsonism linked to chromosome 17 (Pick disease), Alzheimer disease and amyotrophic lateral sclerosis-parkinsonism/dementia complex 1.

Images



SDS-PAGE - Recombinant Human ProSAAS protein (denatured) (ab174456)

15% SDS-PAGE analysis of ab174456 (3 µg)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit **https://www.abcam.com/abpromise** or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors